Chronic wounds may take years to heal and are impactful to a patient’s quality of life, but they can also be a financial burden. As new products come to market, it is essential that efficacy has been established to justify the treatment that the patient is undergoing as well as the cost.
Sickle Cell Gene Therapies and CMS Cell and Gene Therapy Access Model
The federal government has created a program called the Cell and Gene Therapy Access Model, the goal of which is to provide people with Medicaid who have rare and severe diseases access to potentially transformative treatments.
Read moreFirst Gene Therapy for Hearing Loss
The first gene therapy for hearing loss, a dual adeno-associated viral (AAV) vector-based gene therapy, is currently being evaluated in the phase 1/2 AK-OTOF-101 clinical trial (NCT05821959). It seeks to replace the nonfunctioning OTOF gene in the cochlea with a working copy of the OTOF gene.
Read moreGene Therapy Approved for Transfusion-Dependent Thalassemia
With the approval of Casgevy, there are now two gene therapies, Casgevy and Lyfgenia, for the treatment of transfusion dependent thalassemia (TDT).
Read moreIt Costs How Much?!
Most plans have a precertification process in place for high-dollar drugs that addresses the appropriateness for diagnosis as well as provider network status; however, this is where it stops.
Read moreTonya Crawford Recognized by Captive International
Tonya Crawford, Regional Vice President, Employer Stop Loss, has been recognized by Captive International as a Highly Commended Reinsurance Professional.
Read moreBreaking the Cycle: Preventing Neonatal Abstinence Syndrome and Nurturing Healthy Beginnings
When adults withdraw from opioids, we understand that withdrawal symptoms follow. The lesser-known fact is that infants who are born dependent on drugs have horrible withdrawal symptoms, too. The difference is that they are defenseless.
Read moreBlood Cancer: Advancements in CAR-T Cell Therapies
September is Blood Cancer Awareness Month, a global event to help raise awareness of one of the world’s most prevalent and dangerous cancers. Accordingly, we examine advances in research that have the potential to improve treatments and outcomes.
Read moreMetachromatic Leukodystrophy (MLD) and Gene Therapy
Metachromatic Leukodystrophy (MLD) is a rare recessive genetic disorder caused by a mutation in the arylsulfatase-A (ARSA) gene, which normally breaks down sulfatide, resulting in the toxic buildup of lipids and other storage materials in cells in the white matter of the central nervous system and peripheral nerves.
Read moreCell & Gene Therapy Update: July 2023
June was a busy month for the FDA with the approval of two gene therapies, Elevidys (delandistrogene moxeparvovec-rokl) and Roctavian (valoctocogene roxaparvovec-rvox), and one cellular therapy Lantidra (donislecel-jujn). See more about these therapies.
Read more